La Biodiversidad marina como fuente de nuevos agentes anticáncer
|
|
- Bennett Jenkins
- 5 years ago
- Views:
Transcription
1 La Biodiversidad marina como fuente de nuevos agentes anticáncer Marcelino Gutiérrez G. Centro de Biodiversidad y Descubrimiento de Drogas, IDICASAT, Panamá Segundo Simposio Iberoamericano de Investigación en Cáncer de ctubre, 2014, Ilhéus-Ba, Brasil
2 Talk verview 1. Facts about cancer 2. Marine environments and biodiversity 3. Marine organisms as source of natural products and anticancer compounds 4. Stories of success. MP in the market 5. MP in preclinical 6. Role of symbiotic microorganisms as source of MP 7. Conclusions
3 Definition Cancer is the uncontrolled growth and spread of cells. It can affect almost any part of the body. The growths often invade surrounding tissue and can metastasize to distant sites
4 Facts about cancer Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (around 13% of all deaths) in The main types of cancer are: lung (1.37 million deaths) stomach ( deaths) liver ( deaths) colorectal ( deaths) breast ( deaths) cervical cancer ( deaths) About 70% of all cancer deaths occurred in low- and middle-income countries. Deaths from cancer worldwide are projected to continue to rise to over 13.1 million in World ealht rganization, Fact sheet 297, January 2013.
5 Why to search for anticancer compounds in the oceans?
6 ceans cover over 70 % of earth surface
7 Why Marine rganisms? Life started in the oceans There are 11 terrestrial phyla and 28 marine phyla -15 are exclusively marine Marine ecosystems are still a unexplored frontier specially deep-sea and polar regions which comprise 95% of the biosphere. Sessile organisms have evolved developing powerful chemical defenses against predators owadays we have more access to the marine biodiversity (SCUBA, Submarines)
8 Marine rganisms are a rich source of natural products Sponges Cnidarians Ascidians Echinoderms Mollusks Microorganisms Cyanobacteria Bryozoans
9 ot spots of marine biodiversity Amarillo = poca riqueza de especies/ naranja = rico/ rojo = muy rico/ rojo oscuro = regiones con muchas especies endémicas (= hotspots)
10 Marine organisms have provided more than 20,000 compounds over last 50 years All main types of natural products found in land can be found in marine environments More than 500 new compounds/year were isolated from marine sources over the last decade, and about 1000 were reported since 2008 to the present. Several terpenoid-carbon skeletons are exclusively marine
11 Temporal trend in the number of new 1300 MP ( ) More access to the oceans Powerful spectroscopic techniques (MR, MS ) Growing interest from scientists Blunt, J. et al., Marine atural Products, at. Prod. Rep
12 ovel compounds isolated between 1985 and 2008 u, G.P., et al., Mar. Drugs, 2011, 9,
13 Marine atural products isolated in 2011 Blunt, J. W. et al., at Prod. Rep 2013, 30,
14 What happened with all these marine compounds?
15 Stories of success: There are four anticancer MP in the market!
16 Status: FDA Approved Cytarabine (Ara-C) 2 Criptotethya crypta Arabinofuranosyl Cytosine Ara-C, MP derivative Approved 1969 Spongouridine MP Isolated in early 50s Source: Sponge (Criptotethya crypta) Disease area: Acute myeloid leukemia and non-odgkin lymphoma. Molecular target: DA polimerase
17 Status: FDA Approved Trabactedin (ET743) S Ac Ecteinascidin-743 (Yondelis ) Ecteinascidia turbinata Isolated 1986 Approved 2007 There was gap of 38 years in anticancer MP drug discovery! Source: Tunicate (Ecteinascidia turbinata) Disease area: Soft tissue sarcoma and ovarian cancer Molecular target: Minor groove of DA
18 Status: FDA Approved Eribulin Mesylate (alaven) 2 alichondrin B E7389 (Eribulin) Isolated in 1986 (32 stereocenters) Marketed in 2010 (19 stereocenters) Source: Sponge (alichondria okadai) Disease area: Late stage matastatic breast cancer Molecular target: Microtubules
19 Status: FDA Approved Brentuximab vedotin (SG-35) Abm S Monomethylauristatin E 2 Approved 2011 S Dolastatin 10 Isolated in 1987 Source: Mollusk (Dolabella auricularia) Disease area: odgkin s lymphoma, anaplastic large cell lymphoma Molecular target: CD30 and microtubules
20 Brentuximab vedotin Structure
21 Brentuximab vedotin mechanism of action
22 Compounds in phase I-III Clinical trials 11 MP under study
23 Status: Phase III Plitidepsin (Aplidine) Source: Tunicate (Aplidium albicans) Disease area: solid tumors and non-odgkin s lymphoma Molecular target: Rac1 and JK activation
24 Status: Phase III Brentuximab vedotin (SG-35) Abm S MMAE 2 ECEL-1: front-line odgkin lymphoma in combination with chemotherapy ECEL-2: front-line CD30-positive mature T-cell lymphomas in combination with chemotherapy ALCAZA : trial for relapsed CD30-positive cutaneous T-cell lymphoma
25 Status: Phase II Brentuximab vedotin (SG-35) Abm S MMAE 2 1. Relapsed/refractory CD30-positive non-odgkin lymphomas 2. Frontline odgkin lymphoma in patients Frontline diffuse large B-cell lymphoma (+ RCP) 4. CD30-positive non-lymphoma malignancies 5. Retreatment of CD30-positive hematologic malignancies
26 Status: Phase II ADC with MMAF Abm S Monomethylauristatin F 2 S Dolastatin 10 SG-75:Renal cell carcinoma (+ everolimus) (descontinuado) SG CD19A: Acute lympoblastic leukemia, on-odgkin lymphoma
27 Status: Phase II Plinabulin (PI 2358) Phenylahistin (P) Source: Fungus(Aspergillus ustus) Disease area: non-small cell lung cancer Molecular target: Microtubules and JK stress protein
28 Status: Phase II Zalypsis (PM00104) Ac A B C F F F C Ac S Yondelis Source: udibranch (Jorunna funebris) Disease area: Multiple mieloma, bladder and Ewing sarcoma Molecular target: Plasma membrane fluidity
29 Status: Phase II Trabactedin analog (PM01183) S Ac Ac S Source: Tunicate (Ecteinascidia turbinata) Disease area: Resistant ovarian cancer, lung, breast and pancreatic cancer Molecular target: Minor groove of DA, ucleotide Excision Repair
30 Status: Phase I Marizomib (Salinosporamide A) C l Source: Bacteria(Salinispora tropica) Disease area: multiple myeloma Molecular target: 20S proteasome
31 Status: Phase I ASG-22ME Abm S 2 Monomethylauristatin E Source: Mollusk (Dolabella auricularia) Disease area: Solid tumors Molecular target: ectin-4
32 Status: Phase I emiasterlin derivative (E7974) C 2 C 2 emiasterlin Source: Sponge (emiasterella minor) Disease area: solid tumors Molecular target: Microtubules
33 Status: Phase I Bryostatin 1 Source: Briozoan (Bugula neritina) Disease area: Solid tumors, colorectal metastatic cancer Molecular target: Microtubules
34 Role of symbiotic microorganisms as source of MP
35 Same chemotype from organisms so distant? Theonella swinhoei Paederus sp.
36 Entotheonella sp. is responsible for the natural product families isolated from the sponge Theonella swinhoei Wilson, M.C., et al., ature, 2014, doi: /nature12959
37 Yondelis Ac S Eitenascidia turbinata ET-743 Soft tissue sarcoma and ovarian cancer
38 S Candidatus Endoecteinascidia frumentensis 2 2 C Streptomyces lavendulae Myxococcus xanthus Pseudomonas fluorescens Rath, C. M. et al., ACS Chem. Biol. 2011, 6,
39 Marine atural products and MP derivatives that are FDA approved are most likely produced by microorganisms Compound name Collected source organisms Predicted biosynthetic source Disease area Cytarabine (Ara-C) Sponge Bacterium Cancer Eribulin Mesylate Sponge Bacterium Cancer Trabactedin (Yondelis) Tunicate Bacterium Cancer Brentuximab vedotin Mollusk Cyanobacterium Cancer Virabidine (Ara-A) Sponge Bacterium Antiviral Ziconotide Cone Snail Mollusk Pain mega-3-acid ethyl esters Fish Microalgae ypertrigliceridemia Gerwick, W..; Moore, B.S. Chemistry & Biology 2012, 19,
40 Gerwick, W..; Moore, B.S. Chemistry & Biology 2012, 19,
41 Conclusions 1. f approximately 22,000 MP isolated, there are 7 drugs in the market. This means about 1 drug per 3140 MP described. 2. There is a very rich pipeline of MP/MP-derivatives in cancer with 11 compounds in preclinical trials 3. Drugs from the sea have indeed became a reality and oceans and their organisms have proven to be a rich source of drugs 4. There are many niches and marine organisms unexplored and for sure there are many more drugs in the oceans waiting to be discovered 5. ew genomic tools indicate that natural products are not an exhausted recourse. Rather, there is still a universe of molecules just waiting to be discovered.
42 brigado
Productos naturales marinos como fuente de agentes anticáncer
Productos naturales marinos como fuente de agentes anticáncer Marcelino Gutiérrez G. Centro de Biodiversidad y Descubrimiento de Drogas, IDICASAT, Panamá Primer Simposio Iberoamericano de Investigación
More informationMarine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Send rders of Reprints at reprints@benthamscience.net Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 603-631 603 Marine atural Products and Related Compounds as Anticancer Agents: an verview of their
More informationMarine natural products. in clinical trials and on the market. By: Z. Janahmadi
Marine natural products in clinical trials and on the market By: Z. Janahmadi Presentation outline Marine natural products that are under clinical trials, or that have been approved as drugs: Antitumor
More informationAuthor to whom correspondence should be addressed;
Mar. Drugs 2004, 2, 73-82 Marine Drugs ISS 1660-3397 www.mdpi.net/marinedrugs/ Review Drugs and Cosmetics from the Sea Anake Kijjoa 1,* and Pichan Sawangwong 2 1 ICBAS-Instituto de Ciências Biomédicas
More informationDrug development from marine natural products
Drug development from marine natural products Tadeusz F. Molinski*, Doralyn S. Dalisay*, Sarah L. Lievens* and Jonel P. Saludes* Abstract Drug discovery from marine natural products has enjoyed a renaissance
More informationHighlights of these abstracts are presented below:
PharmaMar announces the presentation of 15 abstracts on Yondelis and Aplidin at the 46 th annual meeting of the American Society of Clinical Oncology (ASCO) Madrid, 9 June 2010: PharmaMar SA (Grupo Zeltia,
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationJefferies Global Healthcare Conference New York 2014
Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other
More informationTargeted Cancer Therapies: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Targeted Cancer Therapies:
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationHuman mass balance and metabolite profiling studies of the new anticancer agents plitidepsin, lurbinectedin and niraparib
Human mass balance and metabolite profiling studies of the new anticancer agents plitidepsin, lurbinectedin and niraparib Lotte van Andel ISB: 978-94-9301-411-4 Lotte van Andel Cover design and layout:
More informationMarine Drugs ISSN
Mar. Drugs 211, 9, 514-525; doi:1.339/md94514 Article OPEN ACCESS Marine Drugs ISSN 166-3397 www.mdpi.com/journal/marinedrugs Statistical Research on Marine Natural Products Based on Data Obtained between
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More information1. Introduction. 1.1 Cancer
1. INTRODUCTION 2 1. Introduction 1.1 Cancer Cancer is the second most leading cause of death Worldwide, next to cardiovascular diseases (CVD) 1. It is defined as the uncontrolled growth, spread and proliferation
More informationUnlocking chemical secrets of marine organisms with synthetic biology and the crystalline sponge method
Unlocking chemical secrets of marine organisms with synthetic biology and the crystalline sponge method Roland Kersten Weng lab Whitehead Institute for Biomedical Research atural products in life sciences
More informationAction to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research
Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers
More informationQuestions and Answers About NCI's Natural Products Branch
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More informationHalaven TM FDA Approval Press Conference Statement
Halaven TM FDA Approval Press Conference Statement Haruo Naito President Eisai Co., Ltd. at Tokyo Headquarters Auditorium November 16, 2010 It is with great pleasure that I inform you all here today that
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationIntroduction to Basic Oncology
Introduction to Basic Oncology Cancer Cell AHS 102 Med Term Dr. Susie Turner 1/3/13 General Oncology Study of Tumors Neoplasms/Tumors Abnormal growth of new tissue Are either; Benign or Malignant Onc/o
More informationHEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017
HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths
More informationCell Reproduction Virtual Lab. Interphase Prophase Metaphase Anaphase Telophase. Name
Name THE CELL CYCLE & CANCER WEBQUEST The human body is made up of trillions of cells that continually grow, reproduce and die. How do our bodies make more cells? And, what does this process have to do
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationAviva Group Protection Our guide to cancer
ww For employers use only. Aviva Group Protection Our guide to cancer 1 2 In 2013, 131 million working days were lost due to sickness absence in the UK, at an average of 4.4 working days per employee 1.
More informationMAKING PROGRESS AGAINST CANCER
FIGURE 1 MAKING PROGRESS AGAINST CANCER NUMBER OF CANCER DEATHS PER 100,000 PEOPLE 225 200 175 150 125 4 3 2 1 0 1990 1995 2000 2005 2010 2015 The age-adjusted overall U.S. cancer death rates for adults
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationElution of Tumoricidal Doses of Bortezomib from a Resorbable Cement Carrier
Elution of Tumoricidal Doses of Bortezomib from a Resorbable Cement Carrier Matthew Allen, Vet MB, PhD, Brittani Jones, BS. The Ohio State University, Columbus, OH, USA. Disclosures: M. Allen: 5; Johnson
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationQuarterly Health Topics Series Sanofi s Vision in Oncology. Wednesday, June 13, 2018
Quarterly Health Topics Series Sanofi s Vision in Oncology Wednesday, June 13, 2018 Agenda Sanofi s Vision in Oncology Welcome coffee Advances in Cancer Care Jorge Insuasty, Global Head of Development
More informationSpecific Targeting and Delivery of Therapeutics to Cancer Cells Based on the Tumor Microenvironment
Specific Targeting and Delivery of Therapeutics to Cancer Cells Based on the Tumor Microenvironment Damien Thévenin Department of Chemistry Bioscience in the 21st century (Sep. 14, 218) Anticancer Drugs
More informationCancer Key facts The problem Cancer causes
Cancer Key facts Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008 (1). Lung, stomach, liver, colon and breast cancer cause the most cancer
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationCould marine life cure cancer? perspectives and challenges
15 th International Conference on Environmental Science and Technology Rhodes, Greece, 31 August to 2 September 2017 Could marine life cure cancer? perspectives and challenges Apelia Politi 1, Anastasia
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationNK VUE A DIAGNOSTIC TEST TO MEASURE NK CELL ACTIVITY
NK VUE A DIAGNOSTIC TEST TO MEASURE NK CELL ACTIVITY Are you well equipped to fight cancer and other diseases? Your Immune System Your immune system works much the same way an army would, protecting you
More informationPharmaMar shows new clinical data with Yondelis in different sarcoma subtypes at CTOS 2016
PharmaMar shows new clinical data with Yondelis in different sarcoma subtypes at CTOS 2016 Madrid, November 10 th, 2016.- Within the framework of the 21 st Annual Meeting of the Connective Tissue Oncology
More informationCategories of Cancer. Categorized based on cellular typology
Cancer Chapter 11 Defining Cancer Cancer represents a number of diseases Definition: A collection of cells that reproduce in an uncontrolled way to produce a mass of cells Causes: Chemical Agents; Biological
More informationOverview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology
Overview of Cancer Mylene Freires Advanced Nurse Practitioner, Haematology Aim of the Presentation Review basic concepts of cancer Gain some understanding of the socio-economic impact of cancer Order of
More informationDevelopment status of OPDIVO (nivolumab) 1
August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung
More informationMacmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationMarine actinobacteria: an important source of bioactive natural products
Marine actinobacteria: an important source of bioactive natural products Presented by Akram Najafi Marine actinobacteria Actinobacteria are a group of Gram positive bacteria. They can be terrestrial (soil)
More informationPrecision CAR T Cell Therapeutics. Carl June October 15, 2018
Precision CAR T Cell Therapeutics Carl June October 15, 2018 Disclosure Information Carl June I have the following financial relationships to disclose: Consultant for: Novartis, Immune Design, Viracta,
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More information*It can appear almost anywhere in the body. *The tumor can invade adjoining parts of the body and metastasize to other organs.
CANCER Cancer is an uncontrollable process of growth and cell dissemination. It can appear almost anywhere in the body. The tumor can invade adjoining parts of the body and metastasize to other organs.
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationDevelopment Pipeline Progress Status. February 1, 2019
Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationCell Death and Cancer. SNC 2D Ms. Papaiconomou
Cell Death and Cancer SNC 2D Ms. Papaiconomou How do cells die? Necrosis Death due to unexpected and accidental cell damage. This is an unregulated cell death. Causes: toxins, radiation, trauma, lack of
More informationEvaluación de la toxicidad y del potencial bioactivo de afloramientos de cianobacterias bentónicas arrecifales del Caribe colombiano
Evaluación de la toxicidad y del potencial bioactivo de afloramientos de cianobacterias bentónicas arrecifales del Caribe colombiano Jairo Iván Quintana Bulla Universidad Nacional de Colombia Facultad
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationDevelopment status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 88 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: Oncologic Applications
More informationBIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015
BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the
More informationDr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma
Dr. C. Tom Kouroukis New and upcoming treatments for Lymphoma New and upcoming treatments for Lymphoma Dr. Tom Kouroukis Hamilton Convention Centre November 23, 2013 Overview Importance and design of clinical
More informationCancer in adolescents and Young Adults
17 th ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Cancer in adolescents and Young Adults Laurence Brugières Gustave Roussy Cancer Center Villejuif, France Cancer in TYA A rare disease in
More informationChapter 10-3 Regulating the Cell Cycle
Chapter 10-3 Regulating the Cell Cycle Vocabulary: Cyclin Cancer Key Concepts: How is the cell cycle regulated? How are cancer cells different from other cells? I. Introduction A. An Interesting Fact About
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationNeoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationWelcome! Here s our agenda for today:
Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More information1 Introduction. 1.1 Cancer. Introduction
Introduction 1 1.1 Cancer 1 Introduction Cancer is the most precarious disease characterized by uncontrolled proliferation of cells without any physiological demands of the organism. Cancer may be defined
More informationClinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303
Clinical Policy: (Adcetris) Reference Number: CP.PHAR.303 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAmerican Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.
American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG www.cancer.net www.cancer.net Tell your patients about the ASCO doctor-approved PATIENT INFORMATION WEBSITE Cancer.Net brings the
More informationNeoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture
Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.
More informationP U R D U E U N I V E R S I T Y C E N T E R F O R C A N C E R R E S E A R C H
A U G U S T 2 0 1 7 P U R D U E U N I V E R S I T Y C E N T E R F O R C A N C E R R E S E A R C H TIM'S TWIGS CANCER RESEARCH PROJECTS I N T R O D U C T I O N The fight against cancer begins in the laboratory
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationPlanet Earth Shallow Seas Based on the BBC Planet Earth DVD
Name: Period: Date: Planet Earth Shallow Seas Based on the BBC Planet Earth DVD 1. Why would the majority of ocean life be found in shallow seas, as opposed to the deep ocean? Humpback Whales 2. Why is
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationBL-8040: A Novel CXCR4 Antagonist
BL-8040: A Novel CXCR4 Antagonist December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," plans,
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationIN THE YEAR 2000, approximately 10 million new cases
2002 INTERNATIONAL SYMPOSIUM Anticancer Drug Discovery and Development Throughout the World By G. Schwartsmann, M.J. Ratain, G.M. Cragg, J.E. Wong, N. Saijo, D.R. Parkinson, Y. Fujiwara, R. Pazdur, D.J.
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More information